As many as 40% of U.S. narcotic prescriptions in 2011-2012 were written by only 5% of opioid prescribers, according to a study Express Scripts presented Monday at AcademyHealth's annual research meeting.
The Office of the National Coordinator for Health Information Technology last week issued a policy paper, "A 10-Year Vision to Achieve an Interoperable Health IT Infrastructure," which outlines the government's pledge to support interoperable electronic health records to most Americans.
A report published Friday in the Morbidity and Mortality Weekly Report characterized the 2013-2014 influenza season as the first season since 2009 that H1N1 generated fewer levels of outpatient illness and mortality as compared with seasons when influenza A (H3N2) is predominant.
The Centers for Disease Control and Prevention recently updated a health advisory, recommending an inactivated poliovirus booster for adults traveling to countries with an active wild polio virus in circulation.
Health Media Network and the American College of Cardiology on Wednesday announced a strategic partnership that will significantly increase the size of HMN's Cardiology Network while broadening the distribution of ACC's CardioSmart Initiative.
HDMA on Tuesday honored pharmaceutical and consumer product manufacturers at its 2014 Business and Leadership Conference in Phoenix, through the presentation of the Association’s annual Distribution Industry Awards for Notable Achievements in Healthcare (the DIANA awards).
Sandoz on Tuesday announced an agreement with Upsher-Smith to obtain exclusive U.S. distribution rights for its branded potassium chloride line of products, Klor-Con, and market them under the Sandoz name.
Indian drug maker Wockhardt has been charged by the Food and Drug Administration with utilizing the same unapproved method to test drug quality in its Morton Grove, Ill., facility as two facilities in India, both of which were subsequently banned from importing into the United States,the Wall Street Journal reported Tuesday.
Mylan announced on Monday that it has entered into a settlement and license agreement with Pfizer relating to Mylan's abbreviated new drug application filed with the U.S. Food and Drug Administration for celecoxib capsules in 50-mg, 100-mg, 200-mg and 400-mg strengths.
Teva Pharmaceutical Industries on Monday announced a new organizational structure and executive positions. The changes, which will become effective July 1, are designed to improve global integration and effectiveness across the company, Teva said.
Teva Pharmaceutical Industries announced on Friday that the U.S. District Court for the Northern District of West Virginia has denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex (celecoxib) 100-, 200- and 400-mg capsules.
There may be a connection between taking vasodilators and developing early-stage, age-related macular degeneration, the leading cause of vision loss and blindness among Americans who are ages 65 and older, according to a study published online Wednesday in Ophthalmology, the journal of the American Academy of Ophthalmology.